Cobimetinib (R-enantiomer)

• CAT Number: I005551
• CAS Number: 934660-94-3
• Molecular Formula: C21H21F3IN3O2
• Molecular Weight: 531.31
• Purity: ≥95%
• Synonyms: R-Cobimetinib
• Target: MEK
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C
• IUPAC Name: [3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]-[3-hydroxy-3-[(2R)-piperidin-2-yl]azetidin-1-yl]methanone
• InChI: InChI=1S/C21H21F3IN3O2/c22-14-6-5-13(19(18(14)24)27-16-7-4-12(25)9-15(16)23)20(29)28-10-21(30,11-28)17-3-1-2-8-26-17/h4-7,9,17,26-27,30H,1-3,8,10-11H2/t17-/m1/s1
• InChIKey: BSMCAPRUBJMWDF-QGZVFWFLSA-N
• SMILES: C1CCN[C@H](C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O

Cobimetinib (R-enantiomer)（Cat No.:I005551）is a selective MEK1/2 inhibitor used in cancer treatment. MEK1/2 are key components of the MAPK/ERK signaling pathway, which regulates cell growth, survival, and differentiation. By inhibiting MEK1/2, cobimetinib disrupts cancer cell proliferation and induces apoptosis, particularly in tumors driven by mutations in the RAS/RAF pathway. The R-enantiomer is the active form of cobimetinib, providing enhanced potency and selectivity. It is commonly used in combination with targeted therapies like vemurafenib for the treatment of BRAF V600-mutated metastatic melanoma. Cobimetinib is administered orally.